Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 17/20 | 0.56 |
| ▸ | CTRC | Q99895 | 1/20 | 0.46 |
| ▸ | F7 | P08709 | 1/20 | 0.45 |
| ▸ | F3 | P13726 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2317449 | 1.00 | ELANE (0.56) | ELANECTRCF7F3 | |
| SCHEMBL3846281 | 0.95 | ELANE (0.50) | ELANECTRCF7F3 | |
| SCHEMBL3846277 | 0.95 | ELANE (0.50) | ELANECTRCF7F3 | |
| SCHEMBL12104568 | 0.93 | ELANE (0.61) | ELANECTRCF7F3 | |
| SCHEMBL3847003 | 0.86 | ELANE (0.46) | ELANECTRC | |
| SCHEMBL2358717 | 0.86 | ELANE (0.49) | ELANEF7F3 | |
| SCHEMBL2358720 | 0.86 | ELANE (0.49) | ELANEF7F3 | |
| SCHEMBL1329937 | 0.84 | ELANE (0.52) | ELANECTRC | |
| SCHEMBL1329939 | 0.84 | ELANE (0.52) | ELANECTRC | |
| SCHEMBL2211272 | 0.81 | ELANE (0.54) | ELANECTRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989441-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | claimed |
| US-20090069294-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-03-12 | — | — | US | claimed |
| EP-1902065-A2 | CYCLIC AMIDE DERIVATIVES INHIBITORS OF THE INHIBITOR OF APOPTOSIS PROTEINS, THEIR PREPARATION, AND THEIR USE | Novartis AG (CH) | 2008-03-26 | — | — | EP | claimed |
| WO-2006133147-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-12-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069294-A1 | Organic Compounds | XIAP, BAX, MCL1 | ELANE 2303/4885CTRC 4666/4885F7 4598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.